Blog

Nelson Dusetti: Transforming Pancreatic Cancer Treatment in 2024 – MediaMedic

MediaMedic/LinkedIn

Dec 28, 2024, 13:46

Nelson Dusetti: Transforming Pancreatic Cancer Treatment in 2024 – MediaMedic

MediaMedic shared a post on LinkedIn:

“Dr. Nelson Dusetti: Transforming Pancreatic Cancer Treatment in 2024

In 2024, Dr. Nelson Dusetti, a leading researcher at the Cancer Research Center of Marseille (CRCM), achieved significant milestones in advancing personalized care for pancreatic cancer patients.

This year, Dr. Dusetti presented the Pancreas-View molecular signature test at the American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing its ability to predict individual patient responses to chemotherapy. This innovation allows for personalized treatment plans, improving survival rates and minimizing toxicity.

Dr. Dusetti also integrated artificial intelligence (AI) into oncology by utilizing AI-assisted transcriptomic signatures to address tumor heterogeneity in pancreatic ductal adenocarcinoma (PDAC). These tools help identify the most effective and least toxic chemotherapy options for patients, marking a critical step forward in precision oncology.

Expanding the reach of personalized medicine, his team developed techniques to apply transcriptomic signatures to metastatic pancreatic cancer patients, using fine needle aspiration (FNA) biopsies to predict treatment sensitivity.

Dr. Dusetti’s work in 2024 exemplifies the potential of precision medicine to transform outcomes for pancreatic cancer patients, offering hope through innovation and targeted care.”

Nelson Dusetti, Research Director at INSERM, shared this post, adding:

“2024 was a year full of exciting adventures and improvements.

Here’s to 2025 being even better!”

More posts featuring MediaMedic and Nelson Dusetti.

Nelson Dusetti is the Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.